IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Location: United States, California, Mountain View
Employees: 51-200
Total raised: $102M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.07.2019 | Series C | $102M | - |
Mentions in press and media 9
| Date | Title | Description |
| 18.06.2024 | ViQi Appoints Dr. Tong-Ming Fu M.D., Ph.D, to its Scientific Advisory Board to Accelerate Scientific Innovation Using AI and Imaging | Dr. Tong-Ming Fu, MD, PhD ViQi, Inc., announces the appointment of Dr. Tong-Ming Fu to the ViQi Scientific Advisory Board. This appointment will draw on Dr. Tong-Ming Fu's expertise in virology and his experience with the ViQi flagship AI-b... |
| 07.03.2024 | IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | - |
| 11.10.2021 | The first-ever COVID-19 pill may be just weeks away. A handful of other pills, inhalers, and nasal sprays also show promise. | A man holds a capsule. Photographer, Basak Gurbuz Derman/Getty Images Treating COVID-19 could be simpler soon, thanks to the next generation of treatments. These could come in the form of pills, nasal sprays, or inhalers. On Monday, Merck a... |
| 30.07.2021 | Top Gilead cancer researcher jumps to a startup as Dan Chen exits; Ardelyx gets that CRL we've been waiting for | Chris Takimoto Chris Takimoto, the former CMO at Forty Seven who completed a stint as SVP of oncology R&D at Gilead after the buyout, is moving on. He’s been given the CMO spot at IGM Biosciences. Takimoto is taking t... |
| 09.07.2019 | Three Cancer Drug Developers Raise Big Rounds, Securing Over $500M | 7 Shares Email Facebook Twitter LinkedIn In medical-related funding news, three companies focused on developing treatments, therapies and medicines for cancer patients have announced supergiant rounds. Subscribe to the Crunchbase Daily Acro... |
| 09.07.2019 | IGM Biosciences grabs $102M to push bispecific into the clinic | IGM Biosciences picked up $102 million in series C financing to work on its pipeline of cancer drugs, including a CD20- and CD3-targeting bispecific antibody slated to start clinical trials by the end of the year. Sponsored by Agilent Techn... |
| 09.07.2019 | IGM Biosciences grabs $102M to push bispecific into the clinic | IGM Biosciences picked up $102 million in series C financing to work on its pipeline of cancer drugs, including a CD20- and CD3-targeting bispecific antibody slated to start clinical trials by the end of the year. The capital, garnered from... |
| 09.07.2019 | IGM Biosciences Inks $102M Series C | MOUNTAIN VIEW, CA, IGM Biosciences today announced the closing of its $102 million Series C financing. >> Click here for more funding data on IGM Biosciences >> To export IGM Biosciences funding data to PDF and Excel, click ... |
| 08.07.2019 | IGM Biosciences Raises $102M in Series C Financing | IGM Biosciences, Inc., a Mountain View, Calif.-based biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, closed a $102m Series C financing. New investors included Redmi... |